June 9, 2022 12:20 PM EDTUpdated 03:46 PM
Bioregnum

#BIO22: Com­ing to­geth­er at a crit­i­cal time, End­points News looks at the key met­rics on bio­phar­ma in a tur­bu­lent time

Back at the be­gin­ning of the year dur­ing JP Mor­gan, I came up with my usu­al set of pro­jec­tions for the year ahead and def­i­nite­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times